NL-OMON44056已完成不适用
OPEN-LABEL, RANDOMIZED STUDY TO ASSESS THE SAFETY AS WELL AS THE PHARMACOKINETIC PROFILE AND TO INVESTIGATE THE EFFICACY TRENDS ON BIOMARKERS IN TYPE 2 DIABETES MELLITUS PATIENTS OF A SUSTAINED RELEASE FORMULATION OF EXENATIDE BASED ON MEDUSA* TECHNOLOGY - Exenatide MPF SAD and MAD study
FLAMEL TECHNOLOGIES0 个研究点目标入组 64 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Gender: healthy male or female
- •Age: 18 - 65 years, inclusive
- •Body Mass Index: >22.0 - <35.0 kg/m2 ;Part B:
- •Gender: male or female T2DM patients
- •Age: 18 - 75 years, inclusive
- •Body Mass Index: >25.0 - <40.0 kg/m2
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study
研究者
相似试验
进行中（未招募）
不适用
A study to look at how safe, how well the drug is accepted by the body and how the body deals with the drug when a combination of 5-ALA and SFCare given in different doses in Cancer Patients with Anemia brought on by Chemotherapy.Cancer Patients with Solid Tumors with Chemotherapy Induced AnemiaMedDRA version: 16.1Level: PTClassification code 10002034Term: AnaemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2013-002645-11-GBSBI Pharmaceuticals Co., Ltd.
进行中（未招募）
不适用
A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF AT2101 IN TREATMENT-NAIVE ADULT PATIENTS WITH TYPE 1 GAUCHER DISEASEType 1 Gaucher DiseaseEUCTR2007-003359-35-DEAmicus Therapeutics, Inc.16
进行中（未招募）
不适用
A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF AT2101 IN TREATMENT-NAIVE ADULT PATIENTS WITH TYPE 1 GAUCHER DISEASEType 1 Gaucher DiseaseEUCTR2007-003359-35-GBAmicus Therapeutics, Inc.16
进行中（未招募）
不适用
A Randomized, Open Label Study Assessing Safety, Tolerability, and Efficacy of an Induction/Maintenance Treatment Strategy Including Lopinavir/ritonavir (LPV/r) plus Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) versus Efavirenz (EFV) plus TDF and FTC in Antiretroviral-Naive HIV-1/HCV Co-infected SubjectsTreatment of HIV infection in Antiretroviral-Naive HIV-1/HCV Co-infected Subjects.MedDRA version: 6.1Level: PTClassification code 10020161EUCTR2005-001431-30-ITABBOTT
进行中（未招募）
不适用
A Randomized, Open Label Study Assessing Safety, Tolerability, and Efficacy of an Induction/Maintenance Treatment Strategy Including Lopinavir/ritonavir (LPV/r) plus Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) versus Efavirenz (EFV) plus TDF and FTC in Antiretroviral-Naïve HIV-1/HCV Co-infected SubjectsHIV-1 infectionEUCTR2005-001431-30-IEAbbott GmbH & Co. KG200